Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis

BACKGROUND: The once-daily, all oral, RBV-free, pangenotypic direct-acting anti-viral regimen consisting of co-formulated NS3/4A protease inhibitor glecaprevir and NS5A inhibitor pibrentasvir (G/P), demonstrated high rates of sustained virologic response (SVR) in phase 2 and 3 studies outside Japan....

Descripción completa

Detalles Bibliográficos
Autores principales: Chayama, Kazuaki, Suzuki, Fumitaka, Karino, Yoshiyasu, Kawakami, Yoshiiku, Sato, Ken, Atarashi, Tomofumi, Naganuma, Atsushi, Watanabe, Tsunamasa, Eguchi, Yuichiro, Yoshiji, Hitoshi, Seike, Masataka, Takei, Yoshiyuki, Kato, Koji, Alves, Katia, Burroughs, Margaret, Redman, Rebecca, Pugatch, David L., Pilot-Matias, Tami J., Krishnan, Preethi, Oberoi, Rajneet K., Xie, Wangang, Kumada, Hiromitsu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Japan 2017
Materias:
Original Article—Liver, Pancreas, and Biliary Tract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866824/
https://www.ncbi.nlm.nih.gov/pubmed/28948366
http://dx.doi.org/10.1007/s00535-017-1391-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5866824/
https://www.ncbi.nlm.nih.gov/pubmed/28948366
http://dx.doi.org/10.1007/s00535-017-1391-5

Ejemplares similares